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Introduction: Suboptimal medication adherence among individuals 
with chronic conditions is a significant clinical problem. However, the 
evidence on actual self-reported medication-related morbidity due to 
nonadherence to long-term medications in clinical practice is limited. 
Such evidence is needed to facilitate implementing interventions to 
improve the management and outcomes of long-term medication 
therapies. The objectives of this study was to analyze whether self-
reported adverse drug reactions (ADRs) and subtherapeutic effects 
(STEs) were more common for medications with nonadherent use 
compared with those with adherent use.
Patients (or Materials) and Methods: A survey was administered to a 
random sample of adults (≥ 18 years) drawn by Statistic Sweden from 
the Total Population Register. Survey responses on self-reported ADRs 
and STEs were linked to data from the Swedish Prescribed Drug Register. 
Refill adherence to antihypertensive, lipid-lowering, and oral antidia-
betic medications was measured by using the continuous method of 
medication acquisition (CMA). The percentages of self-reported ADRs 
and STEs were compared between medications used adherently (CMA, 
0.8–1.2), overused (CMA, > 1.2), and underused (CMA, < 0.8).
Results: The study included 1827 individuals aged between 19 
and 96 years old (mean, 68.3 years). Overall, 1656, 818, and 205 
respondents filled, respectively, 3014 antihypertensives, 839 lipid-
lowering, and 235 oral antidiabetic medications. Overall, 65.7% of 
the medications were used adherently, 21.9% overused, and 12.4% 
underused. The proportions of self-reported ADRs and STEs due to 
medications used adherently, overused, and underused were respec-
tively 2.6%, 2.7%, and 2.1% (P > 0.5) for ADRs and 1.1%, 1.6%, 
and 1.5% (P > 0.5) for STEs.
Conclusion: Reported medication-related adverse outcomes 
were similar for medications with adherent and nonadherent use. 
Implementing interventions targeting only the improvement of adher-
ence to long-term prescribed medications may not be associated with 
an improvement of reported medication-related adverse outcomes. 
The impact of individuals and health care factors that may influence 
the association between adherence and medication-related adverse 
outcomes should be investigated to adapt the interventions to the 
population needs.
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Introduction: The Internet has become a global system of interlinked 
networks easy to access from anywhere, with, however, significant 
differences in access and usage between countries. One of the most 
cited reasons for accessing the Internet is searching for health infor-
mation (HI). The objective of our literature review was to examine 
the use of the Internet for seeking HI among patients and the general 
population to investigate who searches for HI on the Internet and for 
what purposes, with a specific focus on medication information (MI).
Patients (or Materials) and Methods: We conducted an electronic 
search using PubMed, Cochrane library, the Banque de Données 
en Santé Publique, and Google scholar for studies published up to 
March 2012. We included articles that studied the general population 
or patients, looking for HI and for MI on the Internet, aged 15 to 80 
years and not suffering from cancer or AIDS.
Results: Sixty-seven studies met the inclusion criteria with 23 of 
these focusing on MI. The studies were conducted in North America 
(45%), Europe (33%), Middle East and Asia (13%), and Australia 
and New Zealand (9%). More than one half of the studies included 
the general population, and 42% evaluated outpatients. Surveys 
were conducted by telephone (n = 26), Internet (n = 11), interviews/
questionnaires (n = 23), or by face-to-face interviews (n = 9), with 
2 studies using 2 different methods.
About one half of the general population and 50% to 99% of 
adults suffering from a chronic disease used the Internet to search 
for HI, mainly about a specific disease, its treatment, exercise, and 
diet. Regarding medications, about one half of the online HI seek-
ers, whether patients or not, looked for MI concerning side effects, 
drug safety, interactions, update on drugs currently consumed, new 
drugs, and over-the-counter or alternate medications. Women, adults 
aged > 50 years, and well-educated people searched significantly more 
frequently for HI and MI. The reasons to search online for MI were 
convenience, broad range of information, and peers’ opinions. The 
online searches for MI did not replace health professionals’ informa-
tion but offered additional information and a possibility to cross-
check. Online MI could reassure or be an incentive to ask questions 
to the treating physicians but also confuse.
Conclusion: Our search highlighted the fact that studies regarding 
the use of the Internet for HI and MI were performed on the general 
population and on outpatients but that no data are available for 
hospitalized patients. Further studies should provide health profes-
sionals with more details on patients’ expectations about online MI. 
This knowledge should enable them to develop online quality MI, 
including Internet-interactive possibilities, in particular for self-man-
agement of chronic diseases.
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Introduction: Several factors have been shown to influence the adher-
ence to chronic treatment, among others the cost of treatment and 
the patients’ perception of the drug effects. In Estonia, campaigns to 
promote the idea of the therapeutic equivalence of the generic drugs 
and reference pricing as well as the legislation on INN-based prescrib-
ing and generic substitution are in use to promote the rational use of 
the resources of the health system, to reduce the patient copayment, 
and at the same time to preserve the adherence to treatment. The aim 
of the study was to analyze the effectiveness on these measures on an 
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example of the antidepressants, a drug group with rapid growth and 
large differences between the originator and generic prices.
Patients (or Materials) and Methods: National ATC/DDD wholesale 
data and the Estonian Health Insurance Fund (EHIF) prescription 
database were used to analyze the antidepressant utilization patterns.
Results: According to the national medicines use data, the total con-
sumption of antidepressants (ADs) was 17.8 defined daily doses per 
1000 inhabitants per day (DID) in Estonia in 2011. During the past 
12 years, the use of these medicines has increased 3-fold (from 5.3 
to 17.8 DID) but is still modest compared with the Nordic countries 
(average consumption of ADs was 77 DID in 2010). The SSRIs con-
stitute about two thirds of the total ADs consumption in Estonia, 
with 11.5 DID in 2011. On the active substance level, there was 
a rapid increase in the use of escitalopram. The average price of 1 
DDD of escitaloprm is 1.01€ for the originator versus 0.30€ for the 
generic. The originator accounts for 20% of the total sale. This is 
similar to the other SSRIs. This may cause substantial patient copay-
ment. We analyzed prescription data from the EHIF to describe in 
detail the use of escitalopram during last years, taking into account 
the patient factors, the prescriber, the cost, and the adherence to treat-
ment expressed via the number of filled prescriptions. The cheapest 
generic generated a 75% lower patient copayment in comparison 
with the originator. In 2011, one half of the new users filled only 1 
prescription. 27% of the new users filling ≥ 2 prescriptions started 
treatment with the originator product, one half of them switched 
treatment to a generic later. Predictors of the originator use and 
adherence were also analyzed.
Conclusion: The average proportion of generic use for the active sub-
stances that have generics on the market is ~60% in Estonia. Where 
the price difference is substantial, the generics fast engage ~80% of 
the market, but even here approximately one fifth of the patients 
stay on the originator product. Reasons and consequences of this 
for the adherence need to be explored further to guide interventions.
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Introduction: The introduction of tyrosinekinase inhibitors (TKI) 
brought a major advance for survival of chronic myeloid leukaemia 
(CML) patients, but as with any other chronic therapy, issues of 
tolerance and adherence are of paramount importance for successful 
clinical outcome.
Patients (or Materials) and Methods: We conducted a structured 
interview concerning patients’ subjective view of their condition and 
history, including the MARS (Medication Adherence Report Scale) 
and BMQ (Beliefs about Medicines Questionnaire) scales to assess 
patients’ perception of their medication and their self-reported adher-
ence. The results were then correlated with trough blood levels of 
imatinib and nilotinib measured as part of routine therapeutic drug 
monitoring to identify patients most at risk of nonadherent behavior. 
We included a total of 38 consecutive patients treated with TKI for 
at least 3 months coming for a regular checkup at clinicof Hemato-
oncology Department of the Faculty Hospital in Olomouc, Czech 
Republic. The population included 20 male and 18 female patients, 
average age 59.6 years (34–75); 21% of patients live alone, 79% 
live with a partner or family, and 18% were university educated. 
Most patients (26 [68%]) were treated with imatinib; dasatinib 
and nilotinib accounted for 16% (6) each. Patients were on average 
7.8 years from diagnosis (0.33–12). On average, patients had 6.15 
years of experience with their current medication; for 82% of them, 
the current TKI was first-line treatment.
Results: Despite the fact that most patients (60%) reported having 
experienced some adverse effects, these were rarely perceived as seri-
ous or bothersome enough to lead to nonadherence. Patients scored 
consistently high on the necessity scale of the BMQ, but most showed 
at least 1 significant concern on the concern scale (87% with at least 
1 score of ≥ 3). The MARS scores showed high adherence – 79% 
scored 24 or 25 out of a 25-point maximum. This is in line with 
the fact that nearly all (95%) of the patients reported that they feel 
sufficiently educated about their disease and treatment. Results from 
questionnaires and demographic data were then correlated with TKI 
trough blood levels and response to the treatment with TKI to analyze 
prognostic impact of nonadherence. Final results will be presented 
at the conference.
Conclusion: Thanks to well-conducted patient education, CML 
patients on TKI perceive the necessity of their treatment, as measured 
by the BMQ scale, and have good adherence rates, as measured by the 
BMQ and MARS scales and TKI trough blood levels, despite experi-
encing a significant number of side effects. Efficient patient education 
at our center that has resulted in better adherence level than reported 
in the previous studies is 1 of the most important preconditions for 
achievement of optimal response to TKI treatment.
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Introduction: Orally disintegrating tablets (ODTs) disintegrate 
immediately in the mouth, and thus patients can consume them 
with little or without any water. These characteristics of ODTs are 
beneficial for patients who have difficulty swallowing conventional 
tablets (CTs) and also for patients with diseases in which water intake 
is restricted. In this study, we evaluated clinical disintegration time of 
17 ODTs that are currently available for clinical use and determined 
the amount of water required to ingest ODTs and CTs.
Patients (or Materials) and Methods: The clinical disintegration time 
was measured for 17 ODT products. Each tablet was placed on the 
tongues of healthy volunteers (n = 18), and disintegrated in their oral 
cavities. The clinical disintegration time of each ODT was measured 
by the investigator with a stopwatch. The residue in the oral cavity 
was removed and rinsed from the mouth with water after the test. 
In the measurement of the volume of water for ingesting of CTs and 
ODTs, which did not include any active pharmaceutical ingredients, 
all volunteers (n = 26) were asked to drink water while consuming 
CTs; while in the case of ODTs, they were asked to drink water after 
the ODT disintegrated in their oral cavity. They freely filled the cup 
with water from the 500-mL bottle and then drank the volume of 
water required to consume each tablet. The amount of water was 
measured using the weight of the cup and bottle. All study protocols 
were approved by the ethics committee of the University of Shizuoka.
Results: To validate the method for measuring the clinical disintegra-
tion time of ODTs, the subjects were randomly assigned to 3 groups, 
and the clinical disintegration times of 2 ODTs were measured. No 
significant difference was observed in the clinical disintegration time 
of each ODT among the 3 groups, which indicated the reproducibility 
